Compare Citius Pharmaceuticals Inc (CTXR) vs Diamondback Energy Inc (FANG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Diamondback Energy Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Diamondback Energy Inc trades at $192.03 (market cap $53.67B). The key difference: Diamondback Energy Inc is far larger — about 3940.5× Citius Pharmaceuticals Inc's market cap, and Diamondback Energy Inc pays a 2.3% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Diamondback Energy Inc for 69 Days on average.
| CTXR | FANG | |
|---|---|---|
Market Cap | $13.62M | $53.67B |
Volume | 132,438 | 2,250,644 |
Sector | Health | Energy |
52-Week High | $1.82 | $213.69 |
52-Week Low | $0.48 | $137.29 |
Typical Hold Time | 17 Days | 69 Days |
Enterprise Value | $3.79M | $65.83B |
Dividend Yield | — | 2.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
Diamondback Energy (FANG) trades at $192.13, up 4.2% in the last session, with a bullish technical signal and strong analyst support. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains solid cash flow from operations. Revenue growth is robust, with 2025 revenue reaching $14.93 billion, though net income margins have compressed. A dividend of $1.10 is scheduled for August 2026, and institutional interest remains high.
The outlook is positive with a consensus price target of $231.77, implying 20% upside. Risks include volatile oil prices and insider selling, but strong Permian Basin positioning and efficient operations support growth. Earnings on November 2, 2026, will be critical for near-term momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Diamondback Energy Inc
Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin. At the end of 2021, the company reported net proven reserves of 1.8 billion barrels of oil equivalent. Net production averaged about 375,000 barrels per day in 2021, at a ratio of 60% oil, 20% natural gas liquids, and 20% natural gas.
Read more on FANG →
